지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 65 - 73 (9page)
이용수
초록· 키워드
오류제보하기
Background/Aims: L-carnitine not only alleviates hyperammonemia and reduces muscle cramps in patients with liver cirrhosis, but also improves anemia in patients with chronic hepatitis and renal dysfunction. This study prospectively evaluated the preventative efficacy of L-carnitine supplementation against hemolytic anemia during antiviral treatment using ribavirin in patients with hepatitis C virus (HCV)-related chronic liver disease. Methods: A total of 41 patients with chronic hepatitis were consecutively enrolled in this study. Group A (n=22) received sofosbuvir plus ribavirin for 3 months, whereas group B (n=19) was treated with sofosbuvir, ribavirin, and L-carnitine. Hemoglobin concentration changes, the effects of antiviral treatment, and the health status of patients were analyzed using short form-8 questionnaires. Results: A significantly smaller decrease in hemoglobin concentration was observed in group B compared to group A at every time point. Moreover, the prescribed dose intensity of ribavirin in group B was higher than that of group A, resulting in a higher ratio of sustained virological response (SVR) 24 in group B compared with group A. The physical function of patients in group B was also significantly improved compared to group A at the end of antiviral treatment. Conclusions: L-carnitine supplementation alleviates ribavirin-induced hemolytic anemia in patients with HCV and helps relieve the physical burden of treatment with ribavirin-containing regimens. These advantages significantly increase the likelihood of achieving SVR.
목차
등록된 정보가 없습니다.
참고문헌 (42)
참고문헌 신청
Takeda H / 2017 / Genetic basis of hepatitis virus-associated hepatocellular carcinoma : linkage between infection, inflammation, and tumorigenesis / J Gastroenterol 52:26~38
Martel-Laferrière V / 2014 / Hepatitis C directacting antiviral agents : changing the paradigm of hepatitis C treatment in HIV-infected patients / J Clin Gastroenterol 48:106~112
Wang LS / 2016 / Hepatitis C-A clinical review / J Med Virol 88:1844~1855
van der Meer AJ / 2016 / Reversion of disease manifestations after HCV eradication / J Hepatol 65(1 Suppl):S95~S108
Gutierrez JA / 2015 / Interferon-free, direct-acting antiviral therapy for chronic hepatitis C / J Viral Hepat 22:861~870
Martel-Laferrière V / 2014 / Hepatitis C directacting antiviral agents : changing the paradigm of hepatitis C treatment in HIV-infected patients / J Clin Gastroenterol 48:106~112
Wang LS / 2016 / Hepatitis C-A clinical review / J Med Virol 88:1844~1855
van der Meer AJ / 2016 / Reversion of disease manifestations after HCV eradication / J Hepatol 65(1 Suppl):S95~S108
Gutierrez JA / 2015 / Interferon-free, direct-acting antiviral therapy for chronic hepatitis C / J Viral Hepat 22:861~870
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
Clinical and Molecular Hepatology
2018 .01
-
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
Clinical and Molecular Hepatology
2018 .01
-
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
Gut and Liver
2020 .01
-
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
Clinical and Molecular Hepatology
2015 .01
-
Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
Gut and Liver
2016 .01
-
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
Gut and Liver
2016 .01
-
Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
Gut and Liver
2019 .01
-
Genotypes of Hepatitis C Virus in Relapsed and Non-respondent Patients and their Response to Anti-Viral Therapy in District Mardan, Khyber Pakhtunkhawa, Pakistan
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
Gut and Liver
2017 .01
-
Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease
Journal of Veterinary Science
2018 .11
-
Hepatitis C Virus and Antiviral Drug Resistance
Gut and Liver
2016 .01
-
Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
Gut and Liver
2017 .07
-
Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data
Gut and Liver
2017 .01
-
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Clinical and Molecular Hepatology
2021 .10
-
Quetiapine Induced Autoimmune Hemolytic Anemia in a Child Patient: A Case Report
Clinical Psychopharmacology and Neuroscience
2018 .01
-
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
Gut and Liver
2017 .01
-
일차성쇼그렌증후군 환자에서 폐결핵 치료 중 발생한 Rifampin 유발 면역용혈성빈혈
대한수혈학회지
2019 .01
-
Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response
Gut and Liver
2016 .01
-
Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
Clinical and Molecular Hepatology
2017 .01
-
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
Gut and Liver
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0